Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 1.00 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.68 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.68 |
| ▸ | TAF1 | P21675 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263200 | 1.00 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL7907534 | 0.89 | ATR (0.80) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263105 | 0.88 | ATR (1.00) | ATRPDCD1CD274PIK3CAMTOR | |
| SCHEMBL21263108 | 0.88 | ATR (1.00) | ATRPDCD1CD274PIK3CAMTOR | |
| SCHEMBL21263161 | 0.87 | ATR (0.79) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263098 | 0.87 | ATR (0.79) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263091 | 0.87 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL22810783 | 0.87 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263177 | 0.86 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263052 | 0.86 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399260-A1 | ATR INHIBITOR AND APPLICATION THEREOF | Wuxi Biocity Biopharmaceutics Co., Ltd. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3753937-A1 | ATR INHIBITOR AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD. (CN) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019154365-A1 | ATR INHIBITOR AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399260-A1 | ATR INHIBITOR AND APPLICATION THEREOF | ATR, ATRIP, CHEK1 | ATR 1/4885ATRIP 2/4885CHEK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.